180 Life Sciences Corp (ATNF)

$3.15

-0.56

(-14.98%)

Market is closed - opens 8 PM, 29 Feb 2024

Insights on 180 Life Sciences Corp

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 72.4% return, outperforming this stock by 166.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 241.2% return, outperforming this stock by 341.0%

Performance

  • $3.00
    $3.90
    $3.15
    downward going graph

    4.76%

    Downside

    Day's Volatility :23.07%

    Upside

    19.23%

    downward going graph
  • $2.85
    $55.10
    $3.15
    downward going graph

    9.52%

    Downside

    52 Weeks Volatility :94.83%

    Upside

    94.28%

    downward going graph

Returns

Period180 Life Sciences CorpRussel 2000Index (Russel 2000)
3 Months
-41.0%
0.0%
0.0%
6 Months
-71.26%
0.0%
0.0%
1 Year
-94.22%
-6.7%
-6.7%
3 Years
-99.82%
-19.6%
-19.6%

Highlights

Market Capitalization
2.1M
Book Value
- $0.02
Earnings Per Share (EPS)
-14.2
Wall Street Target Price
80.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-56.19%
Return On Equity TTM
-312.04%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-17.5M
Diluted Eps TTM
-14.2
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for 180 Life Sciences Corp(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 2439.68%

Current $3.15
Target $80.00

Technicals Summary

Sell

Neutral

Buy

180 Life Sciences Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
180 Life Sciences Corp
180 Life Sciences Corp
-20.86%
-71.26%
-94.22%
-99.82%
-69.45%
Moderna, Inc.
Moderna, Inc.
-7.02%
-15.96%
-29.77%
-38.07%
331.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.33%
18.96%
29.88%
113.28%
129.28%
Novo Nordisk A/s
Novo Nordisk A/s
11.48%
27.69%
72.41%
233.76%
396.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.03%
21.55%
47.08%
102.95%
126.21%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
180 Life Sciences Corp
180 Life Sciences Corp
3.47
NA
NA
0.0
-3.12
-0.56
NA
-0.02
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.94
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.21
28.21
2.0
44.85
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
45.17
45.17
4.45
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.25
31.25
0.59
16.74
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
180 Life Sciences Corp
180 Life Sciences Corp
Buy
$2.1M
-69.45%
3.47
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$35.9B
331.33%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$107.8B
129.28%
28.21
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$544.3B
396.59%
45.17
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$112.0B
126.21%
31.25
36.68%

Institutional Holdings

  • Charles Schwab Investment Management Inc

    3.43%
  • Vanguard Group Inc

    0.47%
  • Renaissance Technologies Corp

    0.43%
  • Geode Capital Management, LLC

    0.30%
  • Virtu Financial LLC

    0.15%
  • BlackRock Inc

    0.14%

Company Information

180 life sciences corp., a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. its product development platforms in phase iib/iii clinical trials include fibrosis and anti-tnf platform, which focuses on fibrosis and anti-tumor necrosis factors; synthetic cannabidiol (cbd) analogs platform, which are man-made derivatives of cbd; and a7nachr platform, which focuses on alpha 7 nicotinic acetylcholine receptor. the company is headquartered in menlo park, california.

Organization
180 Life Sciences Corp
Employees
5
CEO
Sir Marc Feldmann Ph.D.
Industry
Finance

FAQs